Thalidomide-PEG5-COOH

MedChemExpress

®

| Cat. No.: | HY-138773 |
|--------------------|--|
| CAS No.: | 2688100-28-7 |
| Molecular Formula: | C ₂₄ H ₃₀ N ₂ O ₁₁ |
| Molecular Weight: | 522.5 |
| Target: | E3 Ligase Ligand-Linker Conjugates |
| Pathway: | PROTAC |
| Storage: | - 20°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |

SOLVENT & SOLUBILITY

| In Vitro | DMSO : 50 mg/mL (95.69 mM; Need ultrasonic) | | | | | | | |
|----------|--|--|--------------------|-----------|------------|--|--|--|
| | Preparing Stock Solutions | Solvent Mass Concentration | 1 mg | 5 mg | 10 mg | | | |
| | | 1 mM | 1.9139 mL | 9.5694 mL | 19.1388 mL | | | |
| | | 5 mM | 0.3828 mL | 1.9139 mL | 3.8278 mL | | | |
| | | 10 mM | 0.1914 mL | 0.9569 mL | 1.9139 mL | | | |
| | Please refer to the so | lubility information to select the app | propriate solvent. | | | | | |
| In Vivo | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution | | | | | | | |
| | | 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution | | | | | | |
| | 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.98 mM); Clear solution | | | | | | | |

| BIOLOGICAL ACTIVITY | | | |
|---------------------------|--|--|--|
| | | | |
| Description | Thalidomide-PEG5-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology ^[1] . | | |
| IC ₅₀ & Target | Cereblon | | |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |

Product Data Sheet

~______о~_____{OH}

REFERENCES

[1]. Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine. Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11.

[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA